Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis

Cystic Fibrosis Clinical Trial

— Pro-Muco  

Official title:

Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-inflammatory Therapies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00750932
• Other study ID #: AOHP07-PD Pro-Muco
• Secondary ID: DGS2007-0295N° I
• Status: Completed
• Phase: N/A
• First received: September 10, 2008
• Last updated: February 23, 2017
• Start date: January 2008
• Est. completion date: January 2012

Study information

• Verified date: February 2017
• Source: University Hospital, Tours
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the proposed project is to characterize the neutrophile proteases which participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and which are responsible for the degradation of the lung tissue.

The respiratory failure which results from it is one of main causes of the fatal evolution of this pathology but the anti-inflammatory therapies based on the use of antiproteases targeting specifically the soluble elastase did not end, until now, in the hoped results.

The identification of the other noxious targets is a crucial element to give new orientations to the anti-inflammatory strategies based on the administration of antiproteases which remain a promising way.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Man /woman older than 18 years (for adult and group)

• Child aged 6 to 18 years (for child group)

• Suffering from cystic fibrosis in stable condition, ie not having presented thrust acute attack of the broncho-pulmonary or hospitalization for treatment of his illness during the previous 2 weeks

Exclusion Criteria:

• colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia

• non smoker (control group)

• Without history or respiratory respiratory disease known (control group)

• Antibiotic treatment and / or anti-inflammatory drug (NSAID or corticosteroids) in the 2 weeks prior to the inclusion in the study (control group)

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Locations

Country	Name	City	State
France	CHRU de Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France,